At a Glance
- Companies: Gilead Sciences, Genhouse Bio
- Location: Suzhou, China
- Deal value: $80M upfront; up to $1.45B milestones; tiered royalties
- Focus area: Oral MAT2A inhibitor GH31 for MTAP-deleted cancers (~15% solids)
- Next steps: Phase 1 start 2026; Gilead leads global development
What happened?
Gilead Sciences signed a global collaboration with Genhouse Bio for exclusive rights to GH31, an oral synthetic lethal therapy targeting MAT2A in MTAP-deleted solid tumours. Announced 13 February 2026, the deal includes $80 million upfront, up to $1.45 billion in milestones across development, regulatory and sales, plus tiered double-digit royalties. GH31 has IND clearance in the US (Dec 2025) and China (Jan 2026).
Why does it matter?
MTAP deletion occurs in ~15% of cancers (e.g., NSCLC, pancreatic, bladder, glioblastoma), creating a synthetic lethal vulnerability where MAT2A inhibition depletes SAM, disrupting PRMT5-dependent survival in tumour cells while sparing normal ones. This biomarker-driven approach builds on PARP inhibitor success, bolstering Gilead’s precision oncology amid ADC and cell therapy expansion.
Who’s behind it?
Genhouse Bio (Suzhou), incubated by Viva Biotech, advances synthetic lethal assets including PRMT5i and others. Gilead (Nasdaq: GILD), via SVP Oncology Jackson Egen, gains a clinic-ready asset. Genhouse CEO Kuifeng Wang hailed Gilead’s fit for global advancement.
How was it achieved?
GH31 selectively kills MTAP-deleted cells by blocking methionine adenosyltransferase 2A (MAT2A), reducing S-adenosylmethionine (SAM) for methylation pathways. Preclinical data support tumour selectivity; dual INDs enable rapid phase 1 with biomarker cohorts. Competitive landscape includes Agios/IDEAYA MAT2A efforts.
What’s next?
Gilead initiates global phase 1 in 2026 (US/China sites), pursuing biomarker expansion, combinations and breakthrough designation. Technology transfer underway Q1 2026; phase 2/3 by 2027-28, potential launch 2029+. Genhouse eyes HKEX IPO post-deal.
What are people saying?
“This transaction… highlights the global attractiveness of our synthetic lethality innovation,” said Genhouse CEO Kuifeng Wang. Gilead’s Jackson Egen: reflects “disciplined approach to expanding… through innovative science.”